Medicenna is a biotech developing engineered immune proteins (Superkines) to treat cancer, with lead drug MDNA55 in late-stage trials for brain cancer.
No revenue; operating losses of CAD 0.02B annually and CAD 0.01B quarterly, funded by investors, not sales.
Proprietary BiSKITs platform and Superkine pipeline offer potential differentiation, but no approved products or revenue, so competitors like Amgen and Roche can easily outspend and outdevelop them.
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
